LISATA THERAP.INC.DL-001 (8NE) - Total Liabilities
Based on the latest financial reports, LISATA THERAP.INC.DL-001 (8NE) has total liabilities worth €3.14 Million EUR (≈ $3.67 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 8NE net assets growth trend to track the company's year-over-year net asset growth rate.
LISATA THERAP.INC.DL-001 - Total Liabilities Trend (2021–2025)
This chart illustrates how LISATA THERAP.INC.DL-001's total liabilities have evolved over time, based on quarterly financial data.
LISATA THERAP.INC.DL-001 Competitors by Total Liabilities
The table below lists competitors of LISATA THERAP.INC.DL-001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Forum Energy Metals Corp
V:FMC
|
Canada | CA$3.22 Million |
|
Fidelity Emerging Markets Ord
LSE:FEML
|
UK | GBX16.96 Million |
|
Versus Systems Inc
NASDAQ:VS
|
USA | $459.34K |
|
UET United Electronic Technology AG
XETRA:CFC
|
Germany | €49.88 Million |
|
Kibo Energy PLC
JSE:KBO
|
South Africa | ZAC3.83 Million |
|
Bong AB (publ)
ST:BONG
|
Sweden | Skr934.30 Million |
|
Accuracy Shipping Limited
NSE:ACCURACY
|
India | Rs1.83 Billion |
|
Morgan Advanced Materials plc
LSE:MGAM
|
UK | GBX668.20 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down LISATA THERAP.INC.DL-001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LISATA THERAP.INC.DL-001 stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LISATA THERAP.INC.DL-001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LISATA THERAP.INC.DL-001 (2021–2025)
The table below shows the annual total liabilities of LISATA THERAP.INC.DL-001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €3.14 Million ≈ $3.67 Million |
-44.71% |
| 2024-12-31 | €5.68 Million ≈ $6.65 Million |
-16.40% |
| 2023-12-31 | €6.80 Million ≈ $7.95 Million |
+1.34% |
| 2022-12-31 | €6.71 Million ≈ $7.84 Million |
+33.99% |
| 2021-12-31 | €5.01 Million ≈ $5.85 Million |
-- |
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more